Mrs. Gladys Grace Tiwonge Kamanga-sollo, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1723 Broadway St, Suite 410, Cape Girardeau, MO 63701 Phone: 573-332-7746 Fax: 573-339-9709 |
Dr. Jimmy Dayland Bowen, M.D. Physical Medicine & Rehabilitation - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 48 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-388-3045 Fax: 573-335-8424 |
Tracee Michelle Shepard, P.T.A. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3120 Independence St, Cape Girardeau, MO 63703 Phone: 573-651-8242 Fax: 573-651-8246 |
Dr. Paul Joseph Guidos, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2615 Saddle Ridge Ln, Cape Girardeau, MO 63701 Phone: 573-335-4487 |
Im S Hong, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 211 Saint Francis Dr, Cape Girardeau, MO 63703 Phone: 573-331-5329 Fax: 573-331-5085 |
Charissa Lea Griggs, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3047 William St, Cape Girardeau, MO 63703 Phone: 573-339-5989 |
Matthew W Karshner, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2126 Independence St, Cape Girardeau, MO 63703 Phone: 573-986-4404 Fax: 573-986-4439 |
Bernard Charles Burns, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 48 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-335-8257 Fax: 573-335-8424 |
Anna Maria Guidos, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1723 Broadway, Suite 410, Cape Girardeau, MO 63701 Phone: 573-339-1957 Fax: 573-339-9709 |
Heidi Hunter, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 211 Saint Francis Dr, Cape Girardeau, MO 63703 Phone: 573-331-6620 Fax: 573-331-5054 |
News Archive
A cancer tumor's ability to mutate allows it to escape from chemotherapy and other attempts to kill it. So, encouraging mutations would not be a logical path for cancer researchers.
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.
Michael T. Osterholm is Director of the Center for Infectious Disease Research and Policy, Associate Director of the Department of Homeland Security's National Center for Food Protection and Defense, and Professor at the University of Minnesota's School of Public Health.
American Scientific Resources, Inc. (the "Company"), has been informed by Pink OTC Markets Inc. ("Pink Sheets") that the Caveat Emptor designation has been removed from the Company's quotation, and that the full designation of "Pink Sheets Current Information" has now been assigned.
› Verified 3 days ago